Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Menen – page 150

1 845 clinical trials in Menen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Menen at a glance
1 845
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 845 trials in Menen

Open in trial search

Study of IO102-IO103 and Pembrolizumab for Patients with Resectable Melanoma and Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:IO103 acetate
  • Sponsor:Io Biotech ApS

Study on Long-term Safety of Linerixibat for Treating Itchy Skin in Patients with Primary Biliary Cholangitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Linerixibat
  • Sponsor:Glaxosmithkline Research & Development Limited

Renal cell carcinoma

Not recruiting

Study of Pembrolizumab, Belzutifan, and Lenvatinib for Patients with Advanced Clear Cell Renal Cell Carcinoma

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Kite Pharma Inc.

Study on the Effectiveness and Safety of Glofitamab with Drug Combination for Untreated Large B-Cell Lymphoma Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Status epilepticus

Not recruiting

Study on Ganaxolone for Patients with Refractory Status Epilepticus

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ganaxolone
  • Sponsor:Marinus Pharmaceuticals Inc.

Study on the Effects and Safety of Belimumab for Adults with Early Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Neoplasm

Not recruiting

Study on the Safety and Tolerability of Olaparib in Children and Adolescents with Solid Tumors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Acute myeloid leukaemia+1

Not recruiting

Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Haemoptysis

Not recruiting

Study on Tranexamic Acid and Terlipressin for Emergency Treatment of Mild to Severe Hemoptysis in Patients Without Cystic Fibrosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Terlipressin
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Menen

What the registry says about research in the country

01 Advanced Lung Cancer Research

Investigating innovative treatments for Non-Small Cell Lung Cancer (NSCLC), with a focus on patients carrying specific genetic mutations like EGFR Exon 20 insertions. The research evaluates combination therapies using zipalertinib with traditional chemotherapy to improve treatment outcomes.

  • Targeted Therapy Development
  • Genetic Mutation Analysis
  • Combination Treatment Strategies

Studies aim to determine optimal dosing and measure progression-free survival rates in advanced cases.

02 Immunotherapy Research

Evaluating the effectiveness of therapeutic cancer vaccines compared to conventional chemotherapy in treating metastatic NSCLC patients. The research specifically focuses on patients with HLA-A2 positive phenotype who have experienced immunotherapy failure.

  • Cancer Vaccine Development
  • Treatment Resistance Studies
  • Overall Survival Analysis

Research aims to demonstrate improved survival outcomes using novel vaccine-based approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.